In addition, EPHA2 was positively associated with a plethora of adverse clinical characteristics, such as high disease stage, high tumor grade, increased depth of myometrial invasion, low estrogen and progesterone receptors expression, high Ki67 index, and shorter OS [84]. This evidence concerns the gene PGR and neoplasm.